Anti-vaccine Health Secretary Robert F. Kennedy Jr.—who has long dismissed reams of data on lifesaving vaccines as being insufficient to prove safety—is pushing the Food and Drug Administration to lift restrictions on over a dozen injectable peptide treatments. The treatments have little to no efficacy data behind them and were previously banned by the FDA for posing significant safety risks. Kenn...
Anti-vaccine Health Secretary Robert F. Kennedy Jr.—who has long dismissed reams of data on lifesaving vaccines as being insufficient to prove safety—is pushing the Food and Drug Administration to lift restrictions on over a dozen injectable peptide treatments. The treatments have little to no efficacy data behind them and were previously banned by the FDA for posing significant safety risks. Kennedy is a self-proclaimed "big fan" of the risky treatments. Peptides, generally, are chains of amino acids linked together with peptide bonds, a link between the carboxyl group of one amino acid and the amino group of another. Bioactive peptides can have a range of cellular functions and influence various biochemical processes. Well-established, FDA-approved types of peptide drugs include GLP-1s for obesity and insulin for diabetes. But online, peptide drugs are now seemingly synonymous with unproven, non-FDA-approved treatment. They've grown extremely popular among wellness influencers, celebrities, and "biohackers," who claim without evidence that peptides can treat various diseases, reverse aging, and improve appearance. On February 27, Kennedy touted such unproven peptides as a guest on Joe Rogan's podcast, saying he had used them to treat injuries with "really good effect." He also vowed to end the FDA's "war on peptides" and revealed his plan to reverse the FDA's restrictions on many of them. Read full article Comments
Company said it achieved valuation of $852bn, mentioning in a blog post it generates $2bn a month in revenue OpenAI announced on Tuesday it had closed a fundraising round of $122bn and achieved a valuation of $852bn. The funding cements the ChatGPT maker as one of the most highly valued private companies in the world. The artificial intelligence firm received multibillion-dollar investments from c...
Company said it achieved valuation of $852bn, mentioning in a blog post it generates $2bn a month in revenue OpenAI announced on Tuesday it had closed a fundraising round of $122bn and achieved a valuation of $852bn. The funding cements the ChatGPT maker as one of the most highly valued private companies in the world. The artificial intelligence firm received multibillion-dollar investments from companies including Amazon, Nvidia and SoftBank, which committed $110bn, according to the Wall Street Journal . OpenAI also allowed a select group of individual investors to contribute around $3bn. The funding round ranks among the highest-ever in Silicon Valley. Continue reading...
Bloom Productions/DigitalVision via Getty Images My, how time seems to fly! It seemed like not long ago that I last wrote an article about WesBanco, Inc. ( WSBC ). But looking back, the last piece that I published about it came out in August of 2024. At that time, news had just broken that WesBanco and Premier Financial were going to merge in an all-stock deal that valued the latter at $959 millio...
Bloom Productions/DigitalVision via Getty Images My, how time seems to fly! It seemed like not long ago that I last wrote an article about WesBanco, Inc. ( WSBC ). But looking back, the last piece that I published about it came out in August of 2024. At that time, news had just broken that WesBanco and Premier Financial were going to merge in an all-stock deal that valued the latter at $959 million. At that time, I viewed this transaction in a favorable light. Leading up to that point, WesBanco had faced certain financial challenges, though there had been some signs of improvement. I viewed the transaction as appealing based on valuation matters and the prospect that there would be the opportunity for synergies of about $41.4 million. Fast forward to today, and the most recent data available does show some nice results for WesBanco. However, asset quality for the company is mixed, and the stock price is rather lofty in relation to earnings. This creates more of a mixed bag than what we saw back then. My overall assessment is that, on the whole, WesBanco is not a bad prospect. But I do think that there are certainly better opportunities out there today. Because of this, I believe that downgrading WesBanco from a Buy to a Hold makes sense here. I'm No Longer Banking On WesBanco Author - SEC EDGAR Data If you were to analyze WesBanco based only on its fundamentals and not on what caused their change, you would think that the business is growing rapidly on an organic basis. In the chart above, for instance, you can see certain changes to its balance sheet over the last three years. Back in 2023, the company had deposits of $13.17 billion. But those have since ballooned to $21.67 billion as of the end of 2025. This was overwhelmingly thanks to the company's merger with Premier Financial, which brought in $7.9 billion of assets that included $5.9 billion of loans and $1.2 billion of investment securities. Naturally, deposits would have been significant as part of this tra...
Ellen Wald, president of Transversal Consulting and senior fellow at the Atlantic Council, said that despite high oil prices she feels the price of brent should be even higher to reflect the reality of the situation amid the war with Iran. Wald said that the US could better insulate itself from the impacts of future energy crises by improving the interdependence between the US, Canada and Mexico i...
Ellen Wald, president of Transversal Consulting and senior fellow at the Atlantic Council, said that despite high oil prices she feels the price of brent should be even higher to reflect the reality of the situation amid the war with Iran. Wald said that the US could better insulate itself from the impacts of future energy crises by improving the interdependence between the US, Canada and Mexico in North American oil production. (Source: Bloomberg)
Vertex Pharmaceuticals ( VRTX ) has completed its rolling BLA submission to the US FDA for povetacicept for immunoglobulin A nephropathy (IgAN). The company used a priority review voucher with the application and is expecting an FDA review to finish within six months of the BLA's acceptance. Povetacicept is a dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation-inducin...
Vertex Pharmaceuticals ( VRTX ) has completed its rolling BLA submission to the US FDA for povetacicept for immunoglobulin A nephropathy (IgAN). The company used a priority review voucher with the application and is expecting an FDA review to finish within six months of the BLA's acceptance. Povetacicept is a dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand) cytokines, which are both involved in the pathogenesis of several autoimmune diseases. More on Vertex Pharmaceuticals Vertex Pharmaceuticals Incorporated (VRTX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Vertex Pharmaceuticals Incorporated (VRTX) Presents at Leerink Global Healthcare Conference 2026 Transcript Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here's My Take Vertex Pharmaceuticals climbs on positive interim data from IgAN phase 3 trial Key deals this week: KORE, TopBuild, Equinix, PayPal and more
Shares of online advertising giant Alphabet (NASDAQ:GOOGL) jumped 2.9% in the morning session after President Donald Trump signaled a willingness to end the multi-week military conflict with Iran.
Shares of online advertising giant Alphabet (NASDAQ:GOOGL) jumped 2.9% in the morning session after President Donald Trump signaled a willingness to end the multi-week military conflict with Iran.
(RTTNews) - Beyond Meat, Inc. (BYND) on Tuesday reported fourth-quarter net income of $409.9 million, compared to a net loss of $44.9 million in the year-ago period.
(RTTNews) - Beyond Meat, Inc. (BYND) on Tuesday reported fourth-quarter net income of $409.9 million, compared to a net loss of $44.9 million in the year-ago period.
Nvidia (NVDA) started as a video game chipmaker, but became so much more thanks to smart investments. Today, along with GPUs, it makes CPUs, networking equipment, and AI inference accelerators. According to the company’s 10-K form, in fiscal year 2026, its networking revenue totaled $31.4 billion. ...
Nvidia (NVDA) started as a video game chipmaker, but became so much more thanks to smart investments. Today, along with GPUs, it makes CPUs, networking equipment, and AI inference accelerators. According to the company’s 10-K form, in fiscal year 2026, its networking revenue totaled $31.4 billion. ...
Transformational Juniper Merger Drives Step-Change in Scale, Reserves and Earnings Power Transformational Juniper Merger Drives Step-Change in Scale, Reserves and Earnings Power
Transformational Juniper Merger Drives Step-Change in Scale, Reserves and Earnings Power Transformational Juniper Merger Drives Step-Change in Scale, Reserves and Earnings Power
Jonathan Kitchen Wall Street’s major market averages ended higher on Tuesday as an end to the Iran conflict could be near, with President Donald Trump prepared to wind down the military campaign against the country within weeks. The tech-focused Nasdaq Composite ( COMP:IND ) was +3.8%. At the same time, the benchmark S&P 500 ( SP500 ) was +2.9%, and the blue-chip Dow ( DJI ) was +2.5%. Here are th...
Jonathan Kitchen Wall Street’s major market averages ended higher on Tuesday as an end to the Iran conflict could be near, with President Donald Trump prepared to wind down the military campaign against the country within weeks. The tech-focused Nasdaq Composite ( COMP:IND ) was +3.8%. At the same time, the benchmark S&P 500 ( SP500 ) was +2.9%, and the blue-chip Dow ( DJI ) was +2.5%. Here are the 3 stocks to watch on the day: RH ( RH ) plunged nearly 20% in after-hours trading after the high-end furniture retailer reported fourth-quarter results and guidance that disappointed investors. The company posted revenue of $842.6 million, missing estimates of $873.25 million, while adjusted earnings of $1.53 per share fell short of the $2.20 consensus. For the first quarter, RH projected revenue between $781.4 million and $797.7 million, well below the $876.7 million analyst estimate . Nike ( NKE ) slipped 1.3% in postmarket trading, giving back some of its 3.1% regular-session gain, after the athletic apparel giant reported fiscal third-quarter results. Revenue edged up 0.1% year-over-year to $11.3 billion on a reported basis but declined 3% on a constant currency basis, while GAAP EPS of $0.35 came in below last year’s $0.54. Teladoc Health ( TDOC ) could extend its momentum after closing Tuesday’s session up 6% amid activist pressure and a board shakeup. Pineal Capital Management issued an open letter urging the telehealth company to adopt a $200 million-plus share buyback program and conduct a strategic review, including a potential breakup of its integrated care and BetterHelp businesses, arguing the current stock price is “heavily disconnected from the true embedded value.” More on RH, Nike, etc. Wall Street Brunch: Jobs Report Due Despite Holiday Sell Nike: Overpriced On Pandemic-Era Performance And Turnaround Hopes Nike Earnings Preview: The Company Really Needs To Return To Mid-Single-Digit Revenue Growth Teladoc rises following appointment of new board member, ...